CD274 and hepatocellular carcinoma: The CRISPR/Cas9 gene editing technology enables disruption of immune checkpoint gene loci, thereby reducing the expression of PD-1/PD-L1, which helps to decrease the proliferation and spread of cancer cells in patients with end-stage HCC [65,66].